WO2001032928A3 - Methodes permettant de determiner une hypersensibilite a un agent - Google Patents

Methodes permettant de determiner une hypersensibilite a un agent Download PDF

Info

Publication number
WO2001032928A3
WO2001032928A3 PCT/US2000/030474 US0030474W WO0132928A3 WO 2001032928 A3 WO2001032928 A3 WO 2001032928A3 US 0030474 W US0030474 W US 0030474W WO 0132928 A3 WO0132928 A3 WO 0132928A3
Authority
WO
WIPO (PCT)
Prior art keywords
hypersensitivity
gene expression
subject
expression profile
methods
Prior art date
Application number
PCT/US2000/030474
Other languages
English (en)
Other versions
WO2001032928A9 (fr
WO2001032928A2 (fr
Inventor
Spencer Farr
Original Assignee
Phase 1 Molecular Toxicology
Spencer Farr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phase 1 Molecular Toxicology, Spencer Farr filed Critical Phase 1 Molecular Toxicology
Priority to AU14660/01A priority Critical patent/AU1466001A/en
Publication of WO2001032928A2 publication Critical patent/WO2001032928A2/fr
Publication of WO2001032928A9 publication Critical patent/WO2001032928A9/fr
Publication of WO2001032928A3 publication Critical patent/WO2001032928A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des méthodes permettant d'identifier une hypersensibilité chez un sujet par obtention d'un profil d'expression génétique de gènes multiples associés à l'hypersensibilité d'un sujet susceptible de présenter une hypersensibilité, puis d'identifier, dans le profil d'expression génétique de ce sujet, un modèle d'expression génétique des gènes associés à cette hypersensibilité. Le profil d'expression génétique dudit sujet peut être comparé au profil d'expression génétique d'un individu normal et à celui d'un individu présentant une hypersensibilité. Le profil d'expression génétique du sujet ainsi obtenu peut comprendre un profil de niveaux d'ARN messager ou d'ADN complémentaire. Ce profil d'expression génétique peut être obtenu par utilisation d'un jeu ordonné de sondes d'acide nucléique pour la pluralité de gènes associés à l'hypersensibilité. L'expression de gènes associés à l'hypersensibilité est directement liée à la prévention ou la réparation de lésions causées au niveau tissulaire, organique ou systémique par des substances toxiques. L'invention concerne également des bases de données génétiques, des jeux ordonnés d'échantillons ainsi qu'un appareil destinés à l'identification d'une hypersensibilité chez un sujet.
PCT/US2000/030474 1999-11-05 2000-11-03 Methodes permettant de determiner une hypersensibilite a un agent WO2001032928A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU14660/01A AU1466001A (en) 1999-11-05 2000-11-03 Methods of determining individual hypersensitivity to an agent

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16539899P 1999-11-05 1999-11-05
US60/165,398 1999-11-05
US19657100P 2000-04-11 2000-04-11
US60/196,571 2000-04-11

Publications (3)

Publication Number Publication Date
WO2001032928A2 WO2001032928A2 (fr) 2001-05-10
WO2001032928A9 WO2001032928A9 (fr) 2002-05-16
WO2001032928A3 true WO2001032928A3 (fr) 2002-07-25

Family

ID=26861357

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030474 WO2001032928A2 (fr) 1999-11-05 2000-11-03 Methodes permettant de determiner une hypersensibilite a un agent

Country Status (2)

Country Link
AU (1) AU1466001A (fr)
WO (1) WO2001032928A2 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003513613A (ja) * 1999-04-15 2003-04-15 キュラジェン コーポレイション 示差的遺伝子発現を使用する毒性因子の同定方法
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
AU7133000A (en) * 1999-07-02 2001-01-22 Curagen Corporation Method of identifying toxic agents using differential gene expression
WO2002008453A2 (fr) 2000-07-21 2002-01-31 Phase-1 Molecular Toxicology Genes canins de toxicite
US7590493B2 (en) 2000-07-31 2009-09-15 Ocimum Biosolutions, Inc. Methods for determining hepatotoxins
CA2447357A1 (fr) * 2001-05-22 2002-11-28 Gene Logic, Inc. Modelisation en toxicologie moleculaire
ATE483976T1 (de) * 2001-06-05 2010-10-15 Exelixis Inc Gfats als modifikatoren des p53-wegs und verwendungsverfahren
EP1411120B1 (fr) * 2001-07-05 2010-01-13 Taiho Pharmaceutical Company Limited Reseaux d'adn permettant de mesurer la sensibilite a un agent anticancereux
JP2005517400A (ja) * 2001-07-10 2005-06-16 ジーン ロジック インコーポレイテッド 心臓毒分子毒性モデリング
US7447594B2 (en) 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
EP1427850A4 (fr) * 2001-08-16 2006-02-08 Phase 1 Molecular Toxicology I Genes et jeux ordonnes d'echantillons humains pertinents sur le plan toxicologique
KR20040064275A (ko) 2001-11-09 2004-07-16 소스 프리시전 메디슨, 인코포레이티드 유전자 발현 프로파일을 이용한 질병의 동정, 모니터링,치료 및 생물학적 상태의 확인
US7469185B2 (en) 2002-02-04 2008-12-23 Ocimum Biosolutions, Inc. Primary rat hepatocyte toxicity modeling
EP1361433A3 (fr) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Méthode de detemination l'efficacité d'une TNF thérapie
GB0215509D0 (en) * 2002-07-04 2002-08-14 Novartis Ag Marker genes
US20090226374A1 (en) * 2003-10-27 2009-09-10 Health Aide, Inc. Anaphylatoxins for detecting clinical conditions
GB0419481D0 (en) * 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
AU2008226947B2 (en) * 2007-03-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
JP2011125218A (ja) * 2008-04-11 2011-06-30 Signpost Corp 糖尿病患者のフェニルアラニン誘導体系薬物感受性予測方法
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
CN102209541B (zh) 2008-09-08 2016-05-18 小利兰·斯坦福大学托管委员会 醛脱氢酶活性调节剂和其使用方法
US8389522B2 (en) 2008-10-28 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
JP5719985B2 (ja) * 2013-08-01 2015-05-20 株式会社ポーラファルマ ジフェニルメチルピペラジン誘導体
WO2015023675A2 (fr) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Comprimé extrudé anti-abus à libération immédiate
CN103525926B (zh) * 2013-10-08 2016-03-23 浙江大学 一种基于基因表达谱的药物毒性个体易感性基因标志物的筛选方法
WO2015095391A1 (fr) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Comprimé extrudé anti-abus à libération prolongée
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
EP3209282A4 (fr) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Forme galénique anti-abus de remplissage de liquide à libération prolongée
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
CN110974831A (zh) * 2019-10-21 2020-04-10 四川省人民医院 提高氟尿嘧啶敏感性的药物组合及其药物组合的应用
CN110974829A (zh) * 2019-10-21 2020-04-10 四川省肿瘤医院 羟氯喹亚麻酸酯提高5-Fu敏感性的应用及评价方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807680A (en) * 1993-11-12 1998-09-15 The Scripps Research Institute Method for simulataneous identification of differentially expresed mRNAS and measurement of relative concentrations
WO1999023254A1 (fr) * 1997-10-31 1999-05-14 Affymetrix, Inc. Profils d'expression dans des organes d'adultes et de foetus
WO1999037662A1 (fr) * 1998-01-27 1999-07-29 Millennium Pharmaceuticals, Inc. Molecules d'acide nucleique et proteine spoil, et utilisations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807680A (en) * 1993-11-12 1998-09-15 The Scripps Research Institute Method for simulataneous identification of differentially expresed mRNAS and measurement of relative concentrations
WO1999023254A1 (fr) * 1997-10-31 1999-05-14 Affymetrix, Inc. Profils d'expression dans des organes d'adultes et de foetus
WO1999037662A1 (fr) * 1998-01-27 1999-07-29 Millennium Pharmaceuticals, Inc. Molecules d'acide nucleique et proteine spoil, et utilisations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EVANS WILLIAM E ET AL: "Pharmacogenomics: Translating functional genomics into rational therapeutics.", SCIENCE (WASHINGTON D C), vol. 286, no. 5439, 15 October 1999 (1999-10-15), pages 487 - 491, XP002193947, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
AU1466001A (en) 2001-05-14
WO2001032928A9 (fr) 2002-05-16
WO2001032928A2 (fr) 2001-05-10

Similar Documents

Publication Publication Date Title
WO2001032928A3 (fr) Methodes permettant de determiner une hypersensibilite a un agent
Funatsuki et al. Molecular basis of a shattering resistance boosting global dissemination of soybean
Parzies et al. Genetic diversity of barley landrace accessions (Hordeum vulgare ssp. vulgare) conserved for different lengths of time in ex situ gene banks
Owen et al. Assessment of learning by the Morris water task and fear conditioning in inbred mouse strains and F1 hybrids: implications of genetic background for single gene mutations and quantitative trait loci analyses
Davis et al. Genetic basis for susceptibility to noise-induced hearing loss in mice
Glowa et al. Differences in response to an acoustic startle stimulus among forty-six rat strains
CA2202154A1 (fr) Procedes destines a la prospection systematique de medicaments
Yang et al. Construction of a bacterial artificial chromosome (BAC) library and identification of overlapping BAC clones with chromosome 4-specific RFLP markers in rice
WO2004019447A3 (fr) Reseau d'antennes comprenant des elements virtuels
NO20040371L (no) Fremgangsmåte for isolering av mRNA eller cDNA-prober, samt anvendelse derav for fremstilling av et standard diagnostisk gentranskripsjonsmønster og probetestsett og anvendelse av fremgangsmåten for diagnostisering eller identifisering av en sykdom.
JP2004530416A5 (fr)
Ricart et al. N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis
CA2381777A1 (fr) Identification de marqueurs genetiques d'age et de metabolisme biologiques
Gleaves Gene flow mediated by wind-borne pollen
Pasha et al. Variations in angiotensin-converting enzyme gene insertion/deletion polymorphism in Indian populations of different ethnic origins
WO2003004640A1 (fr) Reseaux d'adn permettant de mesurer la sensibilite a un agent anticancereux
WO2002019243A3 (fr) Systeme de mesure corporelle
WO2002016650A3 (fr) Compositions et methodes d'evaluation des niveaux d'expression des exons
Radcliffe et al. Confirmation of contextual fear conditioning QTLs by short-term selection
Caplen et al. Isozymes of the Isoetes riparia complex, I. Genetic variation and relatedness of diploid species
Keightley et al. Testing the correspondence between map positions of quantitative trait loci
WO2002038729A3 (fr) Monitorage des genes et identification des genes a l'aide de reseaux d'adn complementaire
McLaughlin et al. The sediment and erosion control research and education facility at North Carolina State University
Tsumura et al. Allozyme variation of five natural populations of Cryptomeria japonica in western Japan
WO2001011082A3 (fr) Procedes de surveillance d'expression de genes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/12-12/12, DRAWINGS, REPLACED BY NEW PAGES 1/14-14/14; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase